MIP Diagnostics Ltd was founded in 2015 as a spin out from the University of Leicester by several leading experts in the field, including Prof. Sergey Piletsky, in order to commercialise various forms of Molecularly Imprinted Polymers (MIPs), sometimes called "plastic antibodies". Our proprietary technology includes a novel method to make nanoMIPs which circumvents the drawbacks of traditional MIP manufacturing methods. NanoMIPS are, as the name suggests, nanostructured polymer particles typically containing a single binding site for their target. Whilst MIPs are exceptionally robust polymers [plastics], nanoMIPS are sufficiently small to be essentially soluble. They can also be fused to solid substrates, such as sensor surfaces, if required. The robust nature of MIPs and nanoMIPs make them ideal reagents for a wide range of applications including point-of-care diagnostics and in field based testing. They can withstand harsh chemical environments, such as extremes of pH, seawater or high concentrations of organic solvents. MIPs have successfully been created and deployed against all major target classes including peptides, proteins and other macromolecular structures, as well as smaller chemical entities such as drugs, their metabolites and commonly used biochemical species such as enzyme cofactors. Using the proprietary nanoMIP design and development process, MIP Diagnostics can provide a proven nanoMIP within just two weeks of receiving the target.
No immune response is required and no animals are used in the manufacture of MIPs.